Pharmaceutical News

RSS

Medicago announces positive results for H1N1 pandemic vaccine candidate

Medicago today announced that it has achieved additional positive results with its vaccine candidate for the Influenza A (H1N1) virus, also known as Swine flu. Results showed that a single dose of 5 micrograms induced a positive immune response against a new emerging strain of this virus in 100% of vaccinated animals.

31 Jul 2009

New guidelines issued for H1N1 vaccine campaign by Federal Advisory Committee

During a meeting in Atlanta on Wednesday, a "federal advisory committee issued sweeping guidelines … for a vaccination campaign against the pandemic swine flu strain, identifying more than half the U.S. population as targets for the first round of vaccinations," CNN reports (Hellerman, 7/29).

30 Jul 2009

Colchicine approved for acute gout, Mediterranean fever

The U.S. Food and Drug Administration has approved Colcrys to treat acute flairs in patients with gout, a recurrent and painful form of arthritis, and patients with familial Mediterranean fever (FMF), an inherited inflammatory disorder. The medication's active ingredient is colchicine, a complex compound derived from the dried seeds of a plant known as the autumn crocus or meadow saffron (Colchicum autumnale).

30 Jul 2009

Covance enters strategic genomic services agreement with Merck

Covance has announced it has entered into a definitive agreement with Merck & Co., Inc. relating to the supply of genomic analysis services.

30 Jul 2009

Malaria vaccine in the pipeline

Australian scientists have developed the first genetically-engineered malaria vaccine and the vaccine will be trialled in humans early next year.

29 Jul 2009

Swine Flu - getting drugs to the market more rapidly

The pharmaceutical industry has been up in arms this year. Giants such as Pfizer, GSK and AstraZeneca are looking for deals in the downturn whilst competing against increasing generic competition as some of the best selling medicines are coming off patent. In addition to the sectors ever-changing landscape companies are under tremendous pressure from governments to combat the Swine flu pandemic that has gripped the world.

29 Jul 2009

Children needed for Australian swine flu vaccine trial

The child vaccine is similar to the adult one and two types of dose strengths and amounts will be tested in order to determine the correct dosage and the safety of the vaccine - it will be tested on children aged between six months and eight years in Melbourne, Adelaide, Perth, Sydney and Brisbane.

28 Jul 2009

World's first genetically-modified strain of malaria parasite

Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in collaboration with researchers from the US, Japan and Canada, will be trialled in humans from early next year.

28 Jul 2009

Amgen and GlaxoSmithKline to collaborate on Denosumab for postmenopausal osteoporosis

Amgen and GlaxoSmithKline (GSK) today announced a collaboration in which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.

28 Jul 2009

Age-prioritized use of antivirals during an influenza pandemic

A model of influenza transmission and treatment suggests that, if the current swine flu pandemic behaves like the 1918 flu, antiviral treatment should be reserved for the young.

27 Jul 2009

Merck reports proposed settlement involving merger with Schering-Plough

Merck & Co., Inc. has announced a proposed settlement, subject to Court approval, to resolve litigation challenging the planned merger between Merck and Schering-Plough Corporation and seeking other forms of relief.

26 Jul 2009

Global health officials working to prevent H1N1 spread

"Global health officials are scrambling to try to prevent the spread of the H1N1 swine flu virus, with U.S. officials moving Thursday with a recommendation that the Food and Drug Administration (FDA) approve or license a [new H1N1] vaccine," without waiting on the results from "clinical trials to test its safety and efficacy," Wall Street Journal reports (Dooren/Winning, 7/24).

24 Jul 2009

Schering-Plough reports proposed settlement in planned merger with Merck

Schering-Plough Corporation today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to enjoin the planned merger with Merck & Co., Inc., and other forms of relief.

24 Jul 2009

New drug may reduce heart attack damage

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

22 Jul 2009

Costly biologics drugs prompt exclusivity debate

"A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?" The New York Times reports.

22 Jul 2009

Some health groups increase lobbying spending, but only a slight rise overall

"Drug makers, advocacy groups, biotechnology firms and insurance companies have ratcheted up efforts to offer their two cents - and in most cases much, much more - in influencing the health care legislation now working its way through Congress," The New York Times reports.

22 Jul 2009

H1N1 death toll doubles over last month; first vaccine trial begins

The worldwide death toll from the H1N1 (swine flu) virus has doubled in the past month, reaching over 700, the WHO announced Tuesday, the AP/Google.com reports.

22 Jul 2009

Swine flu vaccine trials begin in Australia as death toll tops 700

As Australian scientists embark on the first trials of a swine flu vaccine the World Health Organisation (WHO) has announced that the H1N1 virus (swine flu) has now killed more than 700 people around the world since the outbreak began four months ago.

22 Jul 2009

New drug compound Salirasib brings hope to pancreatic cancer patients

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

20 Jul 2009

Mylan receives FDA approval for additional strengths of antipsychotic Haloperidol

Mylan Inc. has announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Haloperidol Tablets USP, 10 mg and 20 mg. These strengths are in addition to Mylan's currently marketed 0.5 mg, 1 mg, 2 mg and 5 mg strengths of the product.

20 Jul 2009